Working Group on Hypertension in Children and Adolescent

Steering committee
Chairman - Enpar Lurbe, Spain
Vice Chairman – Serap Erdine, Turkey
Secretary - Denes Pall, Hungary

Members
Mario Bianchetti, Switzerland
Kennedy Cruikshank, UK
Tatiana Kuznetsova, Belgium
Mieczyslaw Litwin, Poland
Serafin Malaga, Spain
Nieves Martell, Spain
Wolfgang Rascher, Germany
Franz Schaefer, Germany
Tomas Seeman, Czech Republic
Stella Stabouli, Greece
George Stergiou, Greece
Elke Wühl, Germany

Publications
Lurbe E, Torri Ml
Early vascular phenotypes in the genesis of hypertension
Pediatric Nephrology 2010; 25:763-767

Falkner B, Lurbe E, Schaefer F
High blood pressure in children: clinical and health policy implications
Journal of Clinical Hypertension 2010; 261-276

Lurbe E
Advance in vascular phenotype assessment in children and adolescents
Hypertension 2010; 56:185-186

Journal of Human Hypertension 2010; 24:779-785
Lurbe E, Alvarez J, Redon J
Diagnosis and Treatment of Hypertension in Children
Current Hypertension Reports 2010; 12:480-486

Perpiñá, Cebo0lla A, Botella C, Lurbe E, Torro MI
Emotional eating scale for children and adolescents: Psychometric characteristics in a Spanish sample.

Lurbe E
Hypertension in children and adolescents
European Society of Hypertension Clinical Practice Newsletters 2011; 12:23-24

Cooperative Research Projects

a) Develop accurate non-mercury sphygmomanometer for auscultatory BP measurement and accurate devices for oscillometric BP measurement, and carefully compare values obtained with the two methods in infants, children and adolescents.

b) Obtain robust reference values for office, home and ambulatory BP based on a European pediatric population.

c) Increase knowledge in the use of out-of-office BP measurements.

d) Collect information about early organ damage so as to refine risk stratification and use the information to set intermediate objectives during treatment.

e) Conduct large, long term randomized therapeutic trials using onset of organ damage (such as onset of microalbuminuria and/or left ventricular hypertrophy) to obtain information about when to initiate antihypertensive drug treatment and about the BP goals to achieve.

f) Conduct controlled studies with antihypertensive drugs in order to improve knowledge about specific benefits and disadvantages of BP lowering agents and establish adequate doses.